GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (NAS:FENC) » Definitions » Shiller PE Ratio

FENC (Fennec Pharmaceuticals) Shiller PE Ratio : (As of Apr. 11, 2025)


View and export this data going back to 2002. Start your Free Trial

What is Fennec Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Fennec Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Fennec Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Shiller PE Ratio Chart

Fennec Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fennec Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fennec Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Fennec Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Fennec Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Fennec Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Fennec Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.06/133.1571*133.1571
=-0.060

Current CPI (Dec. 2024) = 133.1571.

Fennec Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 0.010 99.621 0.013
201506 -0.020 100.684 -0.026
201509 -0.010 100.392 -0.013
201512 -0.050 99.792 -0.067
201603 -0.040 100.470 -0.053
201606 -0.060 101.688 -0.079
201609 -0.040 101.861 -0.052
201612 -0.090 101.863 -0.118
201703 -0.060 102.862 -0.078
201706 -0.110 103.349 -0.142
201709 -0.150 104.136 -0.192
201712 -0.150 104.011 -0.192
201803 -0.090 105.290 -0.114
201806 -0.140 106.317 -0.175
201809 -0.140 106.507 -0.175
201812 -0.150 105.998 -0.188
201903 -0.130 107.251 -0.161
201906 -0.240 108.070 -0.296
201909 -0.090 108.329 -0.111
201912 -0.180 108.420 -0.221
202003 -0.190 108.902 -0.232
202006 -0.210 108.767 -0.257
202009 -0.240 109.815 -0.291
202012 -0.120 109.897 -0.145
202103 -0.180 111.754 -0.214
202106 -0.150 114.631 -0.174
202109 -0.160 115.734 -0.184
202112 -0.170 117.630 -0.192
202203 -0.140 121.301 -0.154
202206 -0.190 125.017 -0.202
202209 -0.310 125.227 -0.330
202212 -0.250 125.222 -0.266
202303 -0.230 127.348 -0.240
202306 -0.210 128.729 -0.217
202309 -0.070 129.860 -0.072
202312 -0.100 129.419 -0.103
202403 0.410 131.776 0.414
202406 -0.200 132.554 -0.201
202409 -0.210 133.029 -0.210
202412 -0.060 133.157 -0.060

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fennec Pharmaceuticals  (NAS:FENC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Fennec Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Rosty Raykov director, officer: Chief Executive Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Chris A Rallis director C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Adrian Haigh director 83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27
Robert Andrade officer: Chief Financial Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Marco Maria Brughera director VIALE STEFINI 14, MILANO L6 00000
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Shubh Goel officer: Chief Commercial Officer 1100 MAXWELL, #522, HOBOKEN NJ 07030
Southpoint Capital Advisors Lp 10 percent owner 1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Jodi A Cook director PO BOX 816, NEWTOWN PA 08540
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040